Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
Treatment of Intraocular Melanoma | OBN
Melanoma of the uveal tract (iris, ciliary body, and choroid), though rare, is the most common primary intraocular malignancy in adults. The mean age-adjusted incidence of uveal melanoma in the United States is approximately 4.3 new cases per million people,…
What Causes Nocturnal Lagophthalmos? | OBN
Nocturnal lagophthalmos is the inability to close the eyelids while sleeping. This can result in a range of conditions from mild epithelial changes to severe exposure ulcers (Katz and Kaufman, 1977). Lagophthalmos is associated with exposure keratopathy, poor sleep, and…
4DMT Reports Positive Interim Data for Wet AMD Treatment
4D Molecular Therapeutics (4DMT) announced positive interim data from the Phase 2 PRISM clinical trial, marking a significant stride in the treatment of wet age-related macular degeneration (wet AMD). Arshad M. Khanani, MD, MA, FASRS, presented the data at the…
Kiora, Théa Partner for Retinal Disease Treatment
Kiora Pharmaceuticals has joined forces with Théa Open Innovation (TOI), a sister company of Laboratoires Théa, to develop and commercialize KIO-301 for the treatment of degenerative retinal diseases. The strategic agreement grants Théa exclusive worldwide development and commercialization rights, excluding…
UMass Chan Grants Gene Therapy Licenses to Iveric Bio
UMass Chan Medical School has awarded exclusive global rights for the development and commercialization of innovative adeno-associated virus (AAV) gene therapy products targeting Stargardt disease and Leber congenital amaurosis type 10 (LCA10) to Iveric Bio, an Astellas Company. While gene…
Researcher Cautions on Low-Level Red Light for Myopia
A cautionary note has been sounded by a researcher from the University of Houston’s College of Optometry regarding the use of low-level red light (LLRL) therapy for controlling myopia, particularly in children. Despite recent studies touting its effectiveness in reducing…
Reginald J. Sanders, M.D. Named as New President of the ASRS
Dr. Reginald J. Sanders, a distinguished physician affiliated with the Retina Group of Washington (RGW) and PRISM Vision Group, has been named as the new president of the American Society of Retina Specialists (ASRS). Dr. Sanders holds the distinction of…
Mireca Medicines Gets $1M Boost for Retinal Disease Treatment
Mireca Medicines has been awarded a $989,000 ‘Translational Research Acceleration Program Award’ from the Foundation Fighting Blindness, enabling the company to advance preclinical development of its lead product, MM238. Recognizing Mireca’s pivotal role in targeting the cGMP pathway for treating…
Formosa & Cristália Partner for APP13007 Rights in Brazil
Formosa Pharmaceuticals announced a strategic licensing agreement with Cristália Produtos Químicos Farmacêuticos to secure exclusive commercialization rights for APP13007 (clobetasol propionate ophthalmic nanosuspension, 0.05%) in Brazil. APP13007 is designed for the treatment of inflammation and pain following ocular surgery and…
FDA Approves Modified Axpaxli Trial by Ocular Therapeutix
Ocular Therapeutix announced that the FDA has granted approval for a modification to the special protocol assessment (SPA) agreement for the pivotal phase 3 SOL clinical trial of Axpaxli (axitinib intravitreal implant, also known as OTX-TKI). This modification marks a…